GILD Stock Summary and Trading Ideas (Gilead Sciences | NASDAQ:GILD)

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences trades on the NASDAQ stock market under the symbol GILD.

As of December 31, 2025, GILD stock price declined to $122.74 with 2,720,095 million shares trading.

GILD has a beta of 0.22, meaning it tends to be less sensitive to market movements. GILD has a correlation of 0.03 to the broad based SPY ETF.

GILD has a market cap of $152.30 billion. This is considered a Large Cap stock.

Last quarter Gilead Sciences reported $8 billion in Revenue and $2.47 earnings per share. This beat revenue expectation by $310 million and exceeded earnings estimates by $.33.

In the last 3 years, GILD traded as high as $128.70 and as low as $62.07.

The top ETF exchange traded funds that GILD belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.

GILD has outperformed the market in the last year with a price return of +36.8% while the SPY ETF gained +17.2%. GILD has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +11.3% and +3.3%, respectively, while the SPY returned +2.7% and +0.7%, respectively.

GILD support price is $121.42 and resistance is $124.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GILD shares will trade within this expected range on the day.